Testing first-line antibody plus immunotherapy for mediastinal lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary mediastinal large B-cell lymphoma confirmed by tumor tissue testing
- Your tumor shows CD30 in at least 1% of cells (checked by local lab testing)
- You have not had prior lymphoma treatment (except limited radiation, or a short steroid burst up to 7 days before starting)
- You must be at least 18, and your lymphoma must be measurable on scans (at least 1.5 cm longest size)
- Your blood counts and organ tests must be adequate (including enough neutrophils, platelets, and kidney/liver function)
- You must be able and willing to sign consent and to receive blood transfusions if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
This study tests whether a computer-guided treatment plan can work as well as or better than the standard chemo-immunotherapy for large B-cell lymphoma. It uses a special test after the first cycle to decide who needs a more aggressive approach.
This trial tests whether adding a new targeted drug called birelentinib to the standard chemotherapy combination (R-CHOP) helps people with newly diagnosed aggressive lymphoma. It aims to improve the chances of remission and reduce the risk of the lymphoma coming back.
Hear when a new Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.